Literature DB >> 10178698

Therapeutic immunoadsorption--its role in clinical practice.

N Braun1, J G Kadar, T Risler.   

Abstract

Extracorporeal immunoadsorption onto staphylococcal protein A replaces conventional plasmapheresis because its elimination efficiency is higher while less adverse reactions are seen. Experience in immunoadsorption is limited to specialized centers although recent technical developments make the procedure simple and safe to use. During a workshop held in Munich, September 1996, the application of immunoadsorption in various diseases was discussed. Goodpasture's syndrome, acquired autoimmune coagulopathy, HLA-sensitized transplantation and treatment-resistant life-threatening autoimmune diseases were accepted indications for immunoadsorption. Immunoadsorption in other immunoglobuline and immune complex mediated diseases is still under discussion.

Entities:  

Mesh:

Year:  1998        PMID: 10178698

Source DB:  PubMed          Journal:  Transfus Sci        ISSN: 0955-3886


  3 in total

1.  Immunoadsorption of alloantibodies onto erythroid membrane antigens encapsulated into polymeric microparticles.

Authors:  Valérie Hoffart; Philippe Maincent; Alf Lamprecht; Véronique Latger-Cannard; Véronique Regnault; Christian Merle; Valérie Jouan-Hureaux; Thomas Lecompte; Claude Vigneron; Nathalie Ubrich
Journal:  Pharm Res       Date:  2007-06-14       Impact factor: 4.200

2.  Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.

Authors:  Nuria Pedreño-Lopez; Brandon C Rosen; Walter J Flores; Matthew J Gorman; Thomas B Voigt; Michael J Ricciardi; Kristin Crosno; Kim L Weisgrau; Christopher L Parks; Jeffrey D Lifson; Galit Alter; Eva G Rakasz; Diogo M Magnani; Mauricio A Martins; David I Watkins
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 8.786

Review 3.  Emerging treatment options for the management of pemphigus vulgaris.

Authors:  Khalaf Kridin
Journal:  Ther Clin Risk Manag       Date:  2018-04-27       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.